IMIDs sharing genetic susceptibility within the IL-23/IL-17 pathway respond differently to IL-17 blockade, and while significant clinical benefit was obtained in axial spondyloarthritis (22) and psoriasis (23, 24), IL-17 blockade led to disease worsening in ileal Crohn’s disease (25). Here, IL17A is linked to psoriasis.